{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:52:07Z","timestamp":1794552727559,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Persistence of leukemic stem cells (LSCs) is one of the determining factors to acute myeloid leukemia (AML) treatment failure and responsible for the poor prognosis of the disease. Hence, novel therapeutic strategies that target LSCs are crucial for treatment success. We investigated if targeting Bcl-2 and peroxisome proliferator activated receptor \u03b1 (PPAR\u03b1), two distinct cell survival regulating mechanisms could eliminate LSCs. This study demonstrate that the Bcl-2 inhibitor venetoclax combined with the PPAR\u03b1 agonist chiglitazar resulted in synergistic killing of LSC-like cell lines and CD34<jats:sup>+<\/jats:sup> primary AML cells while sparing their normal counterparts. Furthermore, the combination regimen significantly suppressed AML progression in patient-derived xenograft (PDX) mouse models. Mechanistically, chiglitazar-mediated PPAR\u03b1 activation inhibited the transcriptional activity of the <jats:italic>PIK3AP1<\/jats:italic> gene promoter and down-regulated the PI3K\/Akt signaling pathway and anti-apoptotic Bcl-2 proteins, leading to cell proliferation inhibition and apoptosis induction, which was synergized with venetoclax. These findings suggest that combinatorial Bcl-2 inhibition and PPAR\u03b1 activation selectively eliminates AML cells in vivo and vitro, representing an effective therapy for patients with relapsed and refractory AML.<\/jats:p>","DOI":"10.1038\/s41419-023-06075-6","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T15:05:17Z","timestamp":1693321517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Bcl-2 inhibition combined with PPAR\u03b1 activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia"],"prefix":"10.1038","volume":"14","author":[{"given":"Chendi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongpeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing Z.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9376-3450","authenticated-orcid":false,"given":"Jie","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"6075_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.","journal-title":"Blood Cancer J."},{"key":"6075_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/onc.2010.511","volume":"30","author":"R Majeti","year":"2011","unstructured":"Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011;30:1009\u201319.","journal-title":"Oncogene."},{"key":"6075_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086\u201393.","journal-title":"Nat Med."},{"key":"6075_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI41495","volume":"121","author":"JE Sarry","year":"2011","unstructured":"Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2R\u03b3c-deficient mice. J Clin Invest. 2011;121:384\u201395.","journal-title":"J Clin Invest."},{"key":"6075_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00277-010-1118-7","volume":"90","author":"U Testa","year":"2011","unstructured":"Testa U. Leukemia stem cells. Ann Hematol. 2011;90:245\u201371.","journal-title":"Ann Hematol."},{"key":"6075_CR6","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.critrevonc.2020.102993","volume":"152","author":"Y Tan","year":"2020","unstructured":"Tan Y, Wu Q, Zhou F. Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. Crit Rev Oncol Hematol. 2020;152:102993.","journal-title":"Crit Rev Oncol Hematol."},{"key":"6075_CR7","doi-asserted-by":"publisher","first-page":"1212369","DOI":"10.1155\/2019\/1212369","volume":"2019","author":"Z Han","year":"2019","unstructured":"Han Z, Liang J, Li Y, He J. Drugs and clinical approaches targeting the antiapoptotic protein: a review. Biomed Res Int. 2019;2019:1212369.","journal-title":"Biomed Res Int."},{"key":"6075_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3324\/haematol.2016.163584","volume":"102","author":"W Wang","year":"2017","unstructured":"Wang W, Stiehl T, Raffel S, Hoang VT, Hoffmann I, Poisa-Beiro L, et al. Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia. Haematologica. 2017;102:1567\u201377.","journal-title":"Haematologica."},{"key":"6075_CR9","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","volume":"11","author":"A van Rhenen","year":"2005","unstructured":"van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520\u20137.","journal-title":"Clin Cancer Res."},{"key":"6075_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132:1007\u201312.","journal-title":"Blood."},{"key":"6075_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/17474086.2018.1420474","volume":"11","author":"M Yogarajah","year":"2018","unstructured":"Yogarajah M, Stone RM. A concise review of BCL-2 inhibition in acute myeloid leukemia. Exp. Rev. Hematol. 2018;11:145\u201354.","journal-title":"Exp. Rev. Hematol."},{"key":"6075_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11899-018-0464-8","volume":"13","author":"P Sharma","year":"2018","unstructured":"Sharma P, Pollyea DA. Shutting down acute myeloid leukemia and myelodysplastic syndrome with BCL-2 family protein inhibition. Curr. Hematol. Malig. Rep. 2018;13:256\u201364.","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"6075_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27\u201336.","journal-title":"Cell Death Differ."},{"key":"6075_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40261-019-00779-4","volume":"39","author":"HR Xu","year":"2019","unstructured":"Xu HR, Zhang JW, Chen WL, Ning ZQ, Li XN. Pharmacokinetics, safety and tolerability of chiglitazar, a novel peroxisome proliferator-activated receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study. Clin Drug Investig. 2019;39:553\u201363.","journal-title":"Clin Drug Investig."},{"key":"6075_CR15","doi-asserted-by":"publisher","first-page":"546548","DOI":"10.1155\/2012\/546548","volume":"2012","author":"BK He","year":"2012","unstructured":"He BK, Ning ZQ, Li ZB, Shan S, Pan DS, Ko BC, et al. In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist. PPAR Res. 2012;2012:546548.","journal-title":"PPAR Res."},{"key":"6075_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3214","volume":"12","author":"JM Peters","year":"2012","unstructured":"Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12:181\u201395.","journal-title":"Nat Rev Cancer."},{"key":"6075_CR17","doi-asserted-by":"publisher","first-page":"4313561","DOI":"10.1155\/2017\/4313561","volume":"2017","author":"DS Pan","year":"2017","unstructured":"Pan DS, Wang W, Liu NS, Yang QJ, Zhang K, Zhu JZ, et al. Chiglitazar preferentially regulates gene expression via configuration-restricted binding and phosphorylation inhibition of PPAR\u03b3. PPAR Res. 2017;2017:4313561.","journal-title":"PPAR Res."},{"key":"6075_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/cbf.1691","volume":"28","author":"M Maggiora","year":"2010","unstructured":"Maggiora M, Oraldi M, Muzio G, Canuto RA. Involvement of PPAR\u03b1 and PPAR\u03b3 in apoptosis and proliferation of human hepatocarcinoma HepG2 cells. Cell Biochem Funct. 2010;28:571\u20137.","journal-title":"Cell Biochem Funct."},{"key":"6075_CR19","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.4161\/cc.21015","volume":"11","author":"A Wilk","year":"2012","unstructured":"Wilk A, Urbanska K, Grabacka M, Mullinax J, Marcinkiewicz C, Impastato D, et al. Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. Cell Cycle. 2012;11:2660\u201371.","journal-title":"Cell Cycle."},{"key":"6075_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/leu.2010.117","volume":"24","author":"Z Zak","year":"2010","unstructured":"Zak Z, Gelebart P, Lai R. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha\/NF-kappaB signaling axis. Leukemia. 2010;24:1476\u201386.","journal-title":"Leukemia."},{"key":"6075_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.freeradbiomed.2017.06.002","volume":"110","author":"D Li","year":"2017","unstructured":"Li D, Du Y, Yuan X, Han X, Dong Z, Chen X, et al. Hepatic hypoxia-inducible factors inhibit PPAR\u03b1 expression to exacerbate acetaminophen induced oxidative stress and hepatotoxicity. Free Radic Biol Med. 2017;110:102\u201316.","journal-title":"Free Radic Biol Med."},{"key":"6075_CR22","doi-asserted-by":"publisher","first-page":"35161","DOI":"10.1074\/jbc.M112.367367","volume":"287","author":"J Zhou","year":"2012","unstructured":"Zhou J, Zhang S, Xue J, Avery J, Wu J, Lind SE, et al. Activation of peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) suppresses hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) signaling in cancer cells. J Biol Chem. 2012;287:35161\u20139.","journal-title":"J Biol Chem."},{"key":"6075_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02972-2","volume":"11","author":"K Chen","year":"2020","unstructured":"Chen K, Yang Q, Jie Z, Manman D, Yong Z, Guofeng F, et al. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis. 2020;11:778.","journal-title":"Cell Death Dis."},{"key":"6075_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ebiom.2019.05.003","volume":"44","author":"F Zhang","year":"2019","unstructured":"Zhang F, Li K, Yao X, Wang H, Li W, Wu J, et al. A miR-567-PIK3AP1-PI3K\/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer. EBioMedicine. 2019;44:311\u201321.","journal-title":"EBioMedicine."},{"key":"6075_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11010-021-04290-3","volume":"477","author":"J Li","year":"2022","unstructured":"Li J, Zhang Z, Hu J, Wan X, Huang W, Zhang H, et al. MiR-1246 regulates the PI3K\/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth. Mol Cell Biochem. 2022;477:649\u201361.","journal-title":"Mol Cell Biochem."},{"key":"6075_CR26","doi-asserted-by":"publisher","first-page":"e0036320","DOI":"10.1128\/MCB.00363-20","volume":"41","author":"J Guo","year":"2021","unstructured":"Guo J, Tang T, Li J, Yang Y, Quan Y, Zhang L, et al. Overexpression of MicroRNA 142-5p suppresses the progression of cervical cancer through targeting phosphoinositol-3-kinase adaptor protein 1 expression. Mol Cell Biol. 2021;41:e0036320.","journal-title":"Mol Cell Biol."},{"key":"6075_CR27","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1080\/15384101.2021.1991106","volume":"20","author":"W Tong","year":"2021","unstructured":"Tong W, Zhang H. Overexpression of long non-coding RNA WT1-AS or silencing of PIK3AP1 are inhibitory to cervical cancer progression. Cell Cycle. 2021;20:2583\u201396.","journal-title":"Cell Cycle."},{"key":"6075_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbrc.2020.01.007","volume":"524","author":"A Zhang","year":"2020","unstructured":"Zhang A, Yan S, Cao M, Wu D, Zhou J, Yu Z, et al. Abnormal methylation of PIK3AP1 was involved in regulating the immune inflammatory response of GES-1 cells induced by Helicobacter pylori. Biochem Biophys Res Commun. 2020;524:36\u201342.","journal-title":"Biochem Biophys Res Commun."},{"key":"6075_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu F, Yang X, Geng M, Huang M. Targeting ERK, an Achilles\u2019 Heel of the MAPK pathway, in cancer therapy. Acta Pharm. Sin. B. 2018;8:552\u201362.","journal-title":"Acta Pharm. Sin. B"},{"key":"6075_CR30","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.bbamcr.2010.12.012","volume":"1813","author":"A Plotnikov","year":"2011","unstructured":"Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta. 2011;1813:1619\u201333.","journal-title":"Biochim Biophys Acta."},{"key":"6075_CR31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ajh.25859","volume":"95","author":"M Byrne","year":"2020","unstructured":"Byrne M, Danielson N, Sengsayadeth S, Rasche A, Culos K, Gatwood K, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95:1006\u201314.","journal-title":"Am J Hematol."},{"key":"6075_CR32","doi-asserted-by":"publisher","first-page":"204062072098664","DOI":"10.1177\/2040620720986646","volume":"12","author":"I Aldoss","year":"2021","unstructured":"Aldoss I, Pullarkat V, Stein AS. Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol. 2021;12:2040620720986646.","journal-title":"Ther Adv Hematol."},{"key":"6075_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD Di Nardo","year":"2019","unstructured":"Di Nardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-na\u00efve, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood."},{"key":"6075_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11010-021-04290-3","volume":"477","author":"J Li","year":"2022","unstructured":"Li J, Zhang Z, Hu J, Wan X, Huang W, Zhang H, et al. MiR-1246 regulates the PI3K\/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth. Mol Cell Biochem. 2022;477:649\u201361.","journal-title":"Mol Cell Biochem."},{"key":"6075_CR35","doi-asserted-by":"crossref","unstructured":"Rodon J, Dienstmann R, Serra V, Violeta Serra J Development of PI3K inhibitors: lessons learned from early clinical trials. 2013;10:143\u201353.","DOI":"10.1038\/nrclinonc.2013.10"},{"key":"6075_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.7314\/APJCP.2015.16.6.2129","volume":"16","author":"S Goldar","year":"2015","unstructured":"Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16:2129\u201344.","journal-title":"Asian Pac J Cancer Prev."},{"key":"6075_CR37","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22:4440\u201351.","journal-title":"Clin Cancer Res"},{"key":"6075_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/ AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis."},{"key":"6075_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/onc.2015.120","volume":"35","author":"D-W Wu","year":"2016","unstructured":"Wu D-W, Chen C-Y, Chu C-L, Lee H. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. Oncogene. 2016;35:621\u201330.","journal-title":"Oncogene."},{"key":"6075_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/sj.cdd.4401688","volume":"12","author":"R Ley","year":"2005","unstructured":"Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ. 2005;12:1008\u201314.","journal-title":"Cell Death Differ."},{"key":"6075_CR41","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","volume":"73","author":"M Rahmani","year":"2013","unstructured":"Rahmani M, Mayo Aust M, Attkisson E, Williams Jr DC, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. 2013;73:1340\u201351.","journal-title":"Cancer Res."},{"key":"6075_CR42","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","volume":"78","author":"M Rahmani","year":"2018","unstructured":"Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K induces BAX dependent mitochondrial apoptosis in AML cells. Cancer Res. 2018;78:3075\u201386.","journal-title":"Cancer Res."},{"key":"6075_CR43","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.molcel.2010.11.029","volume":"40","author":"MS Sosa","year":"2010","unstructured":"Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, et al. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell. 2010;40:877\u201392.","journal-title":"Mol Cell."},{"key":"6075_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2006.11.048","volume":"128","author":"D Guo","year":"2007","unstructured":"Guo D, Tan Y-C, Wang D, Madhusoodanan KS, Zheng Y, Maack T, et al. A Rac-cGMP signaling pathway. Cell. 2007;128:341\u201355.","journal-title":"Cell."},{"key":"6075_CR45","doi-asserted-by":"publisher","first-page":"686695","DOI":"10.3389\/fcell.2021.686695","volume":"9","author":"B Li","year":"2021","unstructured":"Li B, Jia R, Li W, Zhou Y, Guo D, Teng Q, et al. PAK1 mediates bone marrow stromal cell-induced drug resistance in acute myeloid leukemia via ERK1\/2 signaling pathway. Front Cell Dev Biol. 2021;9:686695.","journal-title":"Front Cell Dev Biol."},{"key":"6075_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cells9010198","volume":"9","author":"U Degirmenci","year":"2020","unstructured":"Degirmenci U, Wang M, Hu J. Targeting Aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy. Cells. 2020;9:198.","journal-title":"Cells."},{"key":"6075_CR47","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu F, Yang X, Geng M, Huang M. Targeting ERK, an Achilles\u2019 Heel of the MAPK pathway, in cancer therapy. Acta Pharm. Sin. B. 2018;8:552\u201362.","journal-title":"Acta Pharm. Sin. B"},{"key":"6075_CR48","doi-asserted-by":"publisher","first-page":"215997","DOI":"10.1016\/j.canlet.2022.215997","volume":"554","author":"H Zhou","year":"2023","unstructured":"Zhou H, Jiang Y, Huang Y, Zhong M, Qin D, Xie C, et al. Therapeutic inhibition of PPAR\u03b1-HIF1\u03b1-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia. Cancer Lett. 2023;554:215997.","journal-title":"Cancer Lett"},{"key":"6075_CR49","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinsk\u00e1 E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998\u20131013.","journal-title":"Cancer Discov."},{"key":"6075_CR50","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","volume":"75","author":"JW Cassidy","year":"2015","unstructured":"Cassidy JW, Carlos C, Alejandra B. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 2015;75:2963\u20138.","journal-title":"Cancer Res."},{"key":"6075_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02762-w","volume":"11","author":"Y-F Shi","year":"2020","unstructured":"Shi Y-F, Liu L, He L-L, Ye J, Lin Z-J, Yuan D-L, et al. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of BCL-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death and Disease. 2020;11:555.","journal-title":"Cell Death and Disease."},{"key":"6075_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.yjmcc.2014.09.028","volume":"77","author":"M Mussbacher","year":"2014","unstructured":"Mussbacher M, Stessel H, W\u00f6lkart G, Haemmerle G, Zechner R, Mayer B, et al. Role of the ubiquitin-proteasome system in cardiac dysfunction of adipose triglyceride lipase-deficient mice. J Mol Cell Cardiol. 2014;77:11\u20139.","journal-title":"J Mol Cell Cardiol."},{"key":"6075_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2019.07.003","volume":"461","author":"Q Yang","year":"2019","unstructured":"Yang Q, Chen K, Zhang L, Feng L, Fu G, Jiang S, et al. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. Cancer Lett. 2019;461:31\u201343.","journal-title":"Cancer Lett."},{"key":"6075_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05767-3","volume":"14","author":"A-B You","year":"2023","unstructured":"You A-B, Yang H, Lai C-P, Lei W, Yang L, Lin J-L, et al. CMTR1 promotes colorectal cancer cell growth and immune evasion by transcriptionally regulating STAT. Cell Death Dis. 2023;14:245.","journal-title":"Cell Death Dis."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06075-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06075-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T15:05:21Z","timestamp":1693321521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06075-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["6075"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06075-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments have been supervised and approved by the Laboratory Animal Ethics and Management Committee of Xiamen University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"573"}}